Showing 930 results

Filters Content type: News, Editors' picks Topic: Side effects

The most common side effects of anti-HIV drugs are short term and are the result of the body getting used to a new drug. Long-term adverse effects and toxicities are less common.

Cardiovascular disease

People switching from TDF to TAF experience rising cholesterol levels

News
7 May 2020
Side effects

Can This Medicine From a Rainforest Plant Stop Chronic Diarrhea in Folks With HIV?

Editor's pick
TheBody
1 May 2020
PrEP science

Older age and baseline kidney function are the key risk factors for renal dysfunction while taking HIV PrEP

News
23 March 2020
Weight gain & lipodystrophy

Weight gain after starting HIV treatment may have genetic influences

News
18 March 2020
PrEP policies & guidelines

Far fewer people would get PrEP in the US if generic TDF/FTC is replaced with Descovy (TAF/FTC), cost-effectiveness study finds

News
9 March 2020
PrEP science

Uptick in Statin Use After Descovy in HIV PrEP

Editor's pick
Medscape (requires free registration)
9 March 2020
Treatment guidelines

South Africa: Health Department’s dolutegravir plans hit stumbling block

Editor's pick
MedicalBrief
2 March 2020
Side effects

PrEP in pregnancy: safe, but many unanswered questions

News
7 February 2020
Weight gain & lipodystrophy

TreatmentUpdate: weight gain

Editor's pick
CATIE
28 January 2020
PrEP policies & guidelines

Truvada, not Descovy, should be the first choice for PrEP, US experts say

News
14 January 2020
Weight gain & lipodystrophy

What we know about Descovy’s impact on weight & cholesterol

Editor's pick
San Francisco AIDS Foundation
9 January 2020
Bad science & bogus treatments

Facebook disables some misleading ads on HIV prevention drugs, responding to growing outcry

Editor's pick
Washington Post
2 January 2020
PrEP science

Facebook ads push misinformation about HIV prevention drugs, LGBT activists say, ‘harming public health’

Editor's pick
Washington Post
10 December 2019
Changing treatment

Lipid increases after switching from TDF to TAF are reversible when treatment is changed back to TDF

News
10 December 2019
Pharmaceutical industry

Gilead delayed safer HIV drug to extend monopoly profits, advocates allege

Editor's pick
San Francisco Chronicle
6 December 2019
Changing treatment

Caveat emptor: Seven things every patient should know about switching from efavirenz to dolutegravir

Editor's pick
Spotlight
25 November 2019
PrEP science

96-week results of DISCOVER PrEP trial presented at European AIDS Conference

News
14 November 2019
Kidney problems

Tenofovir (TDF) does not increase risk of kidney disease in people at low risk

News
13 November 2019
Weight gain & lipodystrophy

Dolutegravir and raltegravir cause changes to fat cells

News
11 November 2019
Side effects

Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts

News
11 November 2019
Side effects

ADVANCE study shows high frequency of major weight gain in women receiving dolutegravir with TAF

News
8 November 2019
Side effects

Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for cause

News
8 November 2019
Bad science & bogus treatments

Misleading Ads About PrEP Are Threatening Progress to End the HIV Epidemic. They Must Be Removed.

Editor's pick
TheBodyPro
7 November 2019
Side effects

Updated Labeling for Efavirenz-Containing Products Warns of Possible Late-Onset Neurotoxicity

Editor's pick
Monthly Prescribing Reference
31 October 2019